Holen Sie sich die Stockscreener-App
13.40
0.15%
-0.0294
Schlusskurs vom Vortag:
$13.43
Offen:
$13.42
24-Stunden-Volumen:
740.45K
Relative Volume:
0.09
Marktkapitalisierung:
$3.52B
Einnahmen:
$6.16B
Nettoeinkommen (Verlust:
$246.00M
KGV:
14.28
EPS:
0.9387
Netto-Cashflow:
$708.00M
1W Leistung:
-0.22%
1M Leistung:
-0.15%
6M Leistung:
+92.12%
1J Leistung:
+37.54%
1-Tages-Spanne:
$13.40
$13.44
1-Wochen-Bereich:
$13.40
$13.47
52-Wochen-Spanne:
$5.69
$13.49
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, NVS, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.40 | 3.53B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,107.51 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.93 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
231.90 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
149.04 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.17 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-10-27 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
Organon completes licensing deal for hormone-free IUD Miudella By Investing.com - Investing.com Canada
Organon wins rights to first U.S. hormone-free copper IUD in 40 years - Stock Titan
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Lombard Odier Asset Management (USA) Corp's Organon & Co(OGN) Holding History - GuruFocus
Samsung Bioepis, Organon expand Stelara biosimilar partnership to Canada - koreabiomed.com
OGNOrganon & Co Stock Price and Quote - Finviz
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA - Business Wire
Organon and Samsung Bioepis expand Canadian biosimilar deal - grafa.com
Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA®, a Biosimilar Referencing STELARA® in Canada - Businesskorea
Organon gains rights to Samsung biosimilar in Canada By Investing.com - Investing.com Nigeria
Organon gains rights to Samsung biosimilar in Canada - Investing.com
Organon wins FDA nod to expand TOFIDENCE use in severe CRS & COVID-19 - MSN
Organon & Co (OGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FDA expands Organon’s tocilizumab biosimilar indications By Investing.com - Investing.com Nigeria
Organon & Co (OGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organon & Co (OGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Organon & Co (OGN) Institutional Confidence - TradingKey
Organon & Co (OGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Organon & Co (OGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Organon & Co (OGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organon & Co. (OGN) Shareholder/Analyst CallSlideshow (NYSE:OGN) 2026-06-17 - Seeking Alpha
Sun Pharma to buy Organon for $11.75B in record overseas deal - MSN
Organon (OGN) agrees to $14.00 cash merger; special meeting July 23, 2026 - Stock Titan
Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN) - mykxlg.com
Sun Pharma agrees $11.75bn acquisition of Organon - Financier Worldwide
Lost Money on Organon & Co.(OGN)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - GuruFocus
Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)? - Yahoo Finance
Organon (OGN) director Shalini Sharp receives 17,857 phantom stock units as cash-settled award - Stock Titan
Organon (OGN) director Ramona Sequeira receives 17,857 phantom stock units as cash-settled award - Stock Titan
Organon (OGN) director receives 17.8K phantom stock units as compensation - Stock Titan
Organon (OGN) director granted cash-settled phantom stock tied to shares - Stock Titan
Organon (OGN) director awarded 17,857 phantom stock units as cash-settled compensation - Stock Titan
Organon (OGN) director receives phantom stock award, lifting holdings above 81,000 units - Stock Titan
Organon & Co | 4: Statement of changes in beneficial ownership of securities-Director Gayle Helene D - Moomoo
Organon (OGN) director awarded 17,857 phantom stock units under savings plan - Stock Titan
Organon (OGN) director Alan Ezekowitz awarded 17,857 phantom stock units - Stock Titan
Organon (OGN) director awarded phantom stock units tied to shares - Stock Titan
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential - Yahoo Finance
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Press Release: Organon Reports Results for the First Quarter Ended March 31, 2026 - Moomoo
Organon Shareholders Approve Board, Pay and Incentive Plan - The Globe and Mail
Organon & Co. Announces Results of 2026 Annual Meeting and Approves Incentive Stock Plan in Form 8-K Filing - Minichart
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19 - Zacks Investment Research
Sector Gamma AS Has $2.15 Million Stock Position in Organon & Co. $OGN - MarketBeat
Private Management Group Inc. Acquires 1,204,979 Shares of Organon & Co. $OGN - MarketBeat
Organon & Co stock hits 52-week high at 13.48 USD - Investing.com Nigeria
Organon (NYSE: OGN) holders back amended 2021 incentive plan adding 8M shares - Stock Titan
Organon & Co. (NYSE:OGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Brandes Investment Partners LP Has $4.35 Million Stock Holdings in Organon & Co. $OGN - MarketBeat
Organon wins US approval to widen use of arthritis biosimilar drug - ETPharma.com
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):